A Phase 3, Randomized, Open-Label Study of Nivolumab Combined With Cabozantinib Versus Sunitinib in Participants With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 15 Jul 2019
Price : $35 *
At a glance
- Drugs Cabozantinib (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary) ; Sunitinib
- Indications Renal cell carcinoma
- Focus Registrational; Therapeutic Use
- Acronyms CheckMate 9ER
- Sponsors Bristol-Myers Squibb; Exelixis; Ono Pharmaceutical; Takeda
- 25 Jun 2019 Planned End Date changed from 22 Apr 2023 to 14 May 2024.
- 25 Jun 2019 Planned primary completion date changed from 22 Sep 2019 to 30 Jan 2020.
- 14 May 2019 According to an Ipsen media release, top-line results are expected in the first half of 2020.